anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
TCR2 Therapeutics · regulatory-filing

TCR2 Therapeutics | Results Presentation Deck | 34 slides

34 pages · 5 arc beats · 2 loops

Regulatory-Filing Download JSON
Unlock

TCR2 Therapeutics | Results Presentation Deck | 34 slides

TCR2 Therapeutics · 2022-09
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 20 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 4 slides 100% 4/4 slides 100% 4/4 slides · 15 hits
— 0/4 slides
50% 2/4 slides
— 0/4 slides
100% 4/4 slides
— 0/4 slides
Agitate 3 slides 100% 3/3 slides 100% 3/3 slides · 19 hits
— 0/3 slides
— 0/3 slides
100% 3/3 slides 100% 3/3 slides 100% 3/3 slides Solution 11 slides 100% 11/11 slides 100% 11/11 slides · 53 hits
— 0/11 slides
63.6% 7/11 slides · 8 hits 36.4% 4/11 slides 100% 11/11 slides · 13 hits 100% 11/11 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides

Slide inventory

34
every slide · same image gating as the playbook
01
Slide 1
Exhibit 99.2 identifier present.front_matter
Open slide detailBeat · Problem
02
other
Open slide detailBeat · Problem
03
front_matter
Open slide detailBeat · Problem
04
Includes a list of abbreviations at the bottom.summarize
Open slide detailBeat · Problem
05
The slide uses a visual comparison framework to position TRuC-T cells as a superior technological evolution.compare_peers
Open slide detailBeat · AgitateLoop · Cost Of Inaction
06
The slide uses a 2x2 layout to present four distinct experimental results supporting the superiority of TRuC technology.compare_peers
Open slide detailBeat · AgitateLoop · Cost Of Inaction
07
The slide uses a comparative structure to frame gavo-cel as a superior therapeutic option compared to historical anti-mesothelin CAR-T approaches.compare_peers
Open slide detailBeat · AgitateLoop · Cost Of Inaction
08
The chart is a classic waterfall plot used in oncology clinical trials to demonstrate efficacy.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
09
Waterfall plot showing individual patient responses; includes specific clinical trial metrics (ORR, PFS, OS).analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
10
Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction.illustrate_case
Open slide detailBeat · SolutionLoop · Jobs To Be Done
11
Waterfall plot shows individual patient responses; ORR, PFS, and OS metrics provided.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
12
The slide uses a central human anatomy diagram to map specific cancer types to their respective mesothelin expression rates.size_opportunity
Open slide detailBeat · SolutionLoop · Jobs To Be Done
13
The slide uses a vertical process flow to link four strategic modifications to two distinct patient groups (Ovarian/Mesothelioma and NSCLC/Cholangiocarcinoma).plan_implementation
Open slide detailBeat · SolutionLoop · Jobs To Be Done
14
transition
Open slide detailBeat · SolutionLoop · Jobs To Be Done
15
The slide uses a process diagram to illustrate the dose escalation cohorts leading to the Recommended Phase 2 Dose (RP2D).present_framework
Open slide detailBeat · SolutionLoop · Jobs To Be Done
16
RP2D (Recommended Phase 2 Dose) is highlighted at DL 3.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
17
The table categorizes adverse events into Hematologic, On Target/On Tumor, On Target/Off Tumor, and Other, with a specific highlight on the RP2D (Recommended Phanalyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
18
Waterfall plot is a standard clinical trial visualization for tumor response.analyze_data
Open slide detailBeat · SolutionLoop · Jobs To Be Done
19
The chart uses a swimmer plot format to track longitudinal patient data including lymphodepletion status, response type, and survival.analyze_data
Open slide detail
20
The slide presents Kaplan-Meier curves for Progression-Free Survival and Overall Survival alongside a comparative table of historical study data.compare_peers
Open slide detail
21
Includes waterfall plot of target lesion changes and Kaplan-Meier plots for PFS and OS.analyze_data
Open slide detail
22
Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction over time.illustrate_case
Open slide detail
23
The slide uses a scatter plot format with a shared legend for patient IDs and dose levels.analyze_data
Open slide detail
24
Data shows patient-specific longitudinal tracking of transgene copies/µg gDNA.analyze_data
Open slide detail
25
Patients with baseline levels of SMRP in normal range were excluded. Data cutoff: September 9, 2022.analyze_data
Open slide detail
26
transition
Open slide detail
27
The chart displays individual patient responses, with multiple patients achieving significant tumor regression.analyze_data
Open slide detail
28
The slide uses a numbered list format to categorize clinical trial improvements.present_solution
Open slide detail
29
Includes a futility analysis note for MPM arms and collaboration branding.present_framework
Open slide detail
30
The chart shows the breakdown of patient eligibility by MSLN expression levels (50%, 2+/3+ vs 50%, 1+ vs Not eligible).analyze_data
Open slide detail
31
The chart is a swimmer plot showing patient response over time, including redosing events and disease progression.summarize
Open slide detail
32
Uses multiparameter immunofluorescence to visualize tumor markers (PanCK), T cells (CD3), TAMs (CD68), and inhibitory ligands (CD155, PD-L1).diagnose_problem
Open slide detail
33
The chart uses horizontal bars to represent the development stage of each program.plan_implementation
Open slide detail
34
The slide features a large stylized '2' from the company logo as a background element.state_next_steps
Open slide detail